Comparative effectiveness of androgen receptor pathway inhibitor treatment intensification for metastatic hormone-sensitive prostate cancer in real-world patients.

ABSTRACT:

Purpose

This study compared the real-world effectiveness of androgen receptor pathway inhibitors (ARPIs)-abiraterone acetate, apalutamide, and enzalutamide-as treatment intensification in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Materials and methods

This multicenter retrospective cohort study analyzed 219 patients with mHSPC who received first-line ARPIs combined with androgen deprivation therapy. We evaluated progression-free survival to metastatic castration-resistant prostate cancer (PFS to mCRPC) and prostate-specific antigen (PSA) response within 12 weeks and investigated the prognostic impact of early PSA response on clinical outcomes.

Results

The cohort comprised patients receiving abiraterone acetate (n=94, 42.9%), apalutamide (n=91

SUBMITTER: Lee CH 

PROVIDER: S-EPMC12599407 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature